Joel Topf, MD, of Nephrology Times is joined by Cybele Ghossein, MD, Northwestern Medicine; Suneel Udani, MD, Nephrology Associates of Northern Illinois and Indiana; Anthony Chang, MD, University of Chicago; Fernando Fervenza, MD, PhD, Mayo Clinic; and Roger Rodby, MD, Rush University Medical Center, for a roundtable discussion on innovations, insights, and implementation of new treatments for rare kidney disease, in particular, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Researchers uncovered serum proteome biomarkers to predict eGFR decline in patients with ADPKD.
Proposed causes of eGFR difference did not account for its association with adverse outcomes in CKD.
Sex inequities in kidney transplant wait-listing have improved but remain significant, a study found.
Crescents and cellular segmental sclerosis predicted greater benefit from glucocorticoids in IgA nephropathy.
Researchers set out to determine the optimal systolic BP for achieving kidney protection in middle-aged and older patients.
The time of day when antihypertensives are given has little effect on benefits and risks among older, frail patients.
This Freely Filtered episode discusses the use of intranasal desmopressin to help prevent bleeding from kidney biopsy.
The panelists share their excitement about the future of glomerulonephritis therapies.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
Nuvisertib, an oral, investigational, highly selective PIM1 kinase inhibitor, showed clinical activity in a phase 1/2 study.
BE-101 is a single IV infusion which does not require preconditioning or immunosuppression in recipients.
Concizumab-mtci improves thrombin production by blocking the tissue factor pathway inhibitor protein.
In the phase 3 explorer8 trial, concizumab reduced the bleeding rate in patients with hemophilia A and B.
The phase 2a trial is investigating the safety and efficacy of HBI-002, an oral low-dose carbon monoxide therapy.
The agent is already approved to treat thrombocytopenia in adults with chronic ITP for whom prior therapy was unsuccessful.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.